DocGo (NASDAQ:DCGO – Get Free Report) had its price target lowered by equities researchers at Needham & Company LLC from $7.00 to $4.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target suggests a potential upside of 29.45% from the stock’s previous close.
DocGo Stock Performance
NASDAQ:DCGO opened at $3.09 on Friday. The company has a market capitalization of $315.34 million, a price-to-earnings ratio of 11.04, a price-to-earnings-growth ratio of 14.16 and a beta of 1.00. DocGo has a one year low of $2.75 and a one year high of $5.68. The stock has a 50-day simple moving average of $4.58 and a 200 day simple moving average of $4.02.
Insider Buying and Selling at DocGo
In other DocGo news, General Counsel Ely D. Tendler sold 23,088 shares of DocGo stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $4.44, for a total value of $102,510.72. Following the completion of the transaction, the general counsel now directly owns 175,645 shares in the company, valued at $779,863.80. The trade was a 11.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.70% of the stock is currently owned by insiders.
Hedge Funds Weigh In On DocGo
DocGo Company Profile
DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.
Recommended Stories
- Five stocks we like better than DocGo
- What is the Euro STOXX 50 Index?
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- Insider Trading – What You Need to Know
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- How to find penny stocks to invest and trade
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for DocGo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DocGo and related companies with MarketBeat.com's FREE daily email newsletter.